BioCentury
ARTICLE | Emerging Company Profile

One-upping c-MET

How newco Octimet aims to gain an edge in competitive c-MET space

October 20, 2017 4:46 PM UTC

With a plethora of c-MET inhibitors in the clinic for cancer and two on the market, Octimet Oncology N.V. is banking on the dual selectivity of its molecule and its algorithm for identifying responders to gain an advantage.

Octimet was founded in 2016 with exclusive, worldwide rights to OMO-1 and backup compound OMO-2 from Johnson & Johnson. Octimet co-founder and CEO Timothy Perera directed development of both when he was global discovery leader of J&J’s lung disease area. He told BioCentury that J&J completed a successful Phase I trial of OMO-1 but then put the program on hold to focus on immuno-oncology programs...